

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 March 2025 (13.03.2025)



(10) International Publication Number
WO 2025/051868 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) A61P 15/00 (2006.01)
A61K 9/24 (2006.01) A61P 15/12 (2006.01)
A61K 31/519 (2006.01) A61P 15/10 (2006.01)
A61K 31/568 (2006.01)

(21) International Application Number:

PCT/EP2024/074848

(22) International Filing Date:

05 September 2024 (05.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23195531.1 05 September 2023 (05.09.2023) EP
63/580,671 05 September 2023 (05.09.2023) US

(71) Applicant: **FREYA PHARMA SOLUTIONS HOLDING B.V.** [NL/NL]; Kraanspoor 50, 1033SE Amsterdam (NL).

(72) Inventor: **VAN DER MOOREN, Marius Jan**; c/o Freya Pharma Solutions B.V., Kraanspoor 50, 1033SE Amsterdam (NL).

(74) Agent: **SIMMONS & SIMMONS LLP**; Claude Debussylaan 247, 1082MC Amsterdam (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: DRUG DELIVERY SYSTEM FOR THE TREATMENT OF FEMALE SEXUAL INTEREST AND AROUSAL DISORDER

Study Diagram




Figure 1

(57) Abstract: This invention relates to a dual release drug delivery system for use in enhancing female sexual desire in the treatment of Female Sexual Interest and Arousal Disorder (FSIAD). the composition comprises a core comprising cellulose, a filler selected from an organic and/or an inorganic salt, and a first active ingredient comprising a PDE 5 inhibitor for delayed immediate release, a first coating surrounding the core, comprising a hydrophobic polymer and a hydrophilic substance; and a second coating surrounding the first coating, comprising a second active ingredient which is a testosterone, or a functional analogue or derivative of testosterone, for immediate release. The delayed release of the first active ingredient is an immediate release occurring between 2 to 6 hours after the release of the second active ingredient; and the second active ingredient is present in an amount equivalent to from 0.3 to 1.5 mg of testosterone, or in an amount equivalent to no less than 1.0mg of testosterone. In addition, the invention also relates to a method for

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

enhancing female sexual desire in the treatment of Female Sexual Interest and Arousal Disorder (FSIAD).